IAN T. CLARK - 05 Dec 2025 Form 4 Insider Report for Guardant Health, Inc. (GH)

Role
Director
Signature
/s/ John G. Saia, as attorney-in-fact for Ian T. Clark
Issuer symbol
GH
Transactions as of
05 Dec 2025
Transactions value $
-$2,041,662
Form type
4
Filing time
08 Dec 2025, 21:36:19 UTC
Previous filing
05 Aug 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
CLARK IAN T Director 3100 HANOVER STREET, PALO ALTO /s/ John G. Saia, as attorney-in-fact for Ian T. Clark 08 Dec 2025 0001336504

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GH Common Stock Options Exercise $350K +9.11K +92.43% $38.42 19K 05 Dec 2025 By The Thornton-Clark Family Trust, J Thornton-Clark & I Clark TTE Account
transaction GH Common Stock Options Exercise $335K +8.8K +46.44% $38.01 27.8K 05 Dec 2025 By The Thornton-Clark Family Trust, J Thornton-Clark & I Clark TTE Account
transaction GH Common Stock Options Exercise $341K +10.7K +38.56% $31.84 38.5K 05 Dec 2025 By The Thornton-Clark Family Trust, J Thornton-Clark & I Clark TTE Account
transaction GH Common Stock Sale -$870K -8.16K -21.21% $106.67 30.3K 05 Dec 2025 By The Thornton-Clark Family Trust, J Thornton-Clark & I Clark TTE Account F1
transaction GH Common Stock Sale -$1.83M -17.1K -56.28% $107.27 13.3K 05 Dec 2025 By The Thornton-Clark Family Trust, J Thornton-Clark & I Clark TTE Account F2
transaction GH Common Stock Sale -$367K -3.4K -25.66% $108.05 9.85K 05 Dec 2025 By The Thornton-Clark Family Trust, J Thornton-Clark & I Clark TTE Account F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GH Stock Option (Right to Buy) Options Exercise $0 -9.11K -100% $0.00 0 05 Dec 2025 Common Stock 9.11K $38.42 Direct F4
transaction GH Stock Option (Right to Buy) Options Exercise $0 -8.8K -100% $0.00 0 05 Dec 2025 Common Stock 8.8K $38.01 Direct F5
transaction GH Stock Option (Right to Buy) Options Exercise $0 -10.7K -100% $0.00 0 05 Dec 2025 Common Stock 10.7K $31.84 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $105.88 to $106.87. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
F2 Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $106.88 to $107.87. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $107.885 to $108.480. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
F4 The Stock Options vest in full on the one-year anniversary of the grant date, June 15, 2022 or the date of the next year annual stockholders meeting, whichever is earlier.
F5 The stock option vests in full on the one-year anniversary of the grant date, June 14, 2023 or the date of the next year annual stockholders meeting, whichever is earlier.
F6 The stock option vests in full on the one-year anniversary of the grant date, June 12, 2024 or the date of the next year annual stockholders meeting, whichever is earlier.